Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Links between tuberous sclerosis complex and autism, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 17 August.
Links between tuberous sclerosis complex and autism, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 17 August.
The fun and flexibility of data science
Taylor Bolt spent his Ph.D. and postdoc digging through brain imaging data for clues to cognition. In industry, the datasets are different but the joy of answering questions with data remains.
The fun and flexibility of data science
Taylor Bolt spent his Ph.D. and postdoc digging through brain imaging data for clues to cognition. In industry, the datasets are different but the joy of answering questions with data remains.
Mind over metrics: How can we tell if two brains (or AI models) are alike?
The ability to record from large populations of neurons has triggered the development of myriad methods for comparing them. But we’re still grappling with how to convert measures of likeness into a better mechanistic understanding.
Mind over metrics: How can we tell if two brains (or AI models) are alike?
The ability to record from large populations of neurons has triggered the development of myriad methods for comparing them. But we’re still grappling with how to convert measures of likeness into a better mechanistic understanding.